Fennec Pharmaceuticals Inc. (FENC) Dividend History

Fennec Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare and life-threatening pediatric diseases. The company's lead candidate, seek to address unmet medical needs by advancing therapies that improve patient outcomes in areas such as oncology and pain management.

Po Box 13628, Research Triangle Park, NC, 27709
Phone: (919) 636-4530
Website:

Dividend History

Fennec Pharmaceuticals Inc. currently does not pay dividends

Company News

  • Fennec Announces Results of Annual Meeting

    Fennec Pharmaceuticals reported strong first-quarter 2025 financial results, with total net revenues up 18% year-over-year. The company attributed the positive momentum to its refined sales strategy and enhanced patient support services.

    GlobeNewswire Inc.
  • Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany

    Fennec Pharmaceuticals' PEDMARQSI has been approved in the EU and U.K. as the first and only therapy to prevent hearing loss caused by cisplatin chemotherapy in pediatric patients with solid tumors. Norgine Pharmaceuticals has launched PEDMARQSI in Germany, accelerating its global commercialization.

    GlobeNewswire Inc.
  • Fennec Pharmaceuticals Announces Management Change

    RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 2024. After nine years as an independent director, in August 2023, Adrian joined the Fennec leadership team as Chief Operating Officer.

    GlobeNewswire Inc.
  • Fennec Announces Results of Annual Meeting

    Annual meeting voting results.

    GlobeNewswire Inc.
  • Adherex Technologies Inc. (FENC) Lags Q1 Earnings Estimates

    Adherex Technologies (FENC) delivered earnings and revenue surprises of -16.33% and 142.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
    Featured Companies: GANX
Dividend data last updated 06/07/2025 02:25:32 UTC